Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis (ALS) Clear all
No Longer Available No phase listed Expanded access

Intermediate-Sized Expanded Access Study

NCT05597436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Trehalose
Drug
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

NCT03929068
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
carbidopa-levodopa, Placebo Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 11, 2026, 5:34 PM EDT
Recruiting Phase 1 Interventional

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
View directory record Official record
Conditions
ALS
Interventions
AMX0114, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
lithium carbonate
Drug
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
21 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 11, 2026, 5:34 PM EDT
Completed No phase listed Observational

Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis

NCT00339976
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 11, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

NCT06910384
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
STR04
Biological
Lead sponsor
New England Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 11, 2026, 5:34 PM EDT
Recruiting No phase listed Observational

ALS/MND Natural History Study Data Repository

NCT05966038
View directory record Official record
Conditions
ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
14
States / cities
Loma Linda, California • Los Angeles, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

NCT02525471
View directory record Official record
Conditions
ALS
Interventions
RNS60
Drug
Lead sponsor
Sabrina Paganoni, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

NCT02936635
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
tirasemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ozanezumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 11, 2026, 5:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis

NCT00023075
View directory record Official record
Conditions
Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria

NCT03613038
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Parkinson Disease
Interventions
Phonetic complexity effects on speech motor performance
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
19 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Fairway, Kansas • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 11, 2026, 5:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Regimen I NUZ-001

NCT07410806
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NUZ-001, Matching placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

NCT00070993
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine monohydrate
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

NCT01906658
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Repository corticotropin injection
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 11, 2026, 5:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 11, 2026, 5:34 PM EDT
Completed No phase listed Observational

Delineating Swallowing Impairment and Decline in ALS

NCT02962050
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Videofluoroscopic Swallowing Study (VFSS), Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Eating Assessment Tool 10, The Center for Neurologic Study Bulbar Function Scale
Procedure · Device · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 11, 2026, 5:34 PM EDT
Completed Not applicable Interventional

An Online Mindfulness Intervention for People With ALS and Their Caregivers

NCT03095989
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Mindfulness
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 11, 2026, 5:34 PM EDT
Completed No phase listed Observational

Real World Testing of a Brain-Computer Interface

NCT04026581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury, Speech Disorders
Interventions
Speech generating device (SGD) evaluation including BCI access, Training and treatment
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Carnegie, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 11, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04579666
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2), Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 11, 2026, 5:34 PM EDT
Completed No phase listed Observational

Amyotrophic Lateral Sclerosis (ALS) Gulf War Study

NCT00007722
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2009 · Synced Oct 11, 2026, 5:34 PM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 11, 2026, 5:34 PM EDT